期刊文献+

蛋白质的氨甲酰化作为慢性肾衰时的生物标志物

下载PDF
导出
摘要 许多研究已证实氨基甲酰化的蛋白质涉及各种疾病的进展,特别是慢性肾衰。本文的目的是介绍非酶促蛋白质翻译后修饰的概况以及其在体内的影响,并评价其作为生物标志物的临床用途。
作者 王继贵
出处 《实验与检验医学》 CAS 2013年第5期409-411,共3页 Experimental and Laboratory Medicine
  • 相关文献

参考文献16

  • 1Jaisson S.Gillery P.Evaluation of nonenzymatic posttranslational modification-derived products as biomarkers of molecular ageing of proteins[J].Clin Chem,2010,56(9):1401-1412.
  • 2Baynes JW.The clinical chemome:a tool for the diagnosis and man- agement of chronic disease[J]. Clin Chem 2004,50(7): 1116-1117.
  • 3Kraus LM,Kraus AP Jr.Carbamoylation of amino acids,and proteins in uremia[J].Kidney Int, 2001,78(Suppl):S102-S107.
  • 4Wang Z,Nicholls SJ,Rodriguez ER,et al.Protein carbamylation links inflammation,smoking, uremia and atherogenesis [J].Nat Med,2007, 13(10):1176-1184.
  • 5Harding JJ.Viewing molecular mechanisms of ageing through a lens [J].Ageing Res Rev,2002,1(3):465-479.
  • 6Jaisson S,Lorimier S,Ricard-Blum S,et al.lmpact of carbamylation on type I collagen conformationM structure and its ability to acti- vate human polymorphonuclear neutrophils [J]. Chem Biol,2006, 13(2):149-159.
  • 7Ha E,Bang JH,Son JN,et al.Carbamylated albumin,stimulates mi- croRNA-146, which is increased in human renal cell carcinoma [J].Mol Med Report,2010,3(2):275-279.
  • 8Apostolov EO,Ray D,Savenka AV,et al.Chronic uremia stimulate LDL Carbamylation and atherosclerosis [J].J Am Soc Nephrol,2010, 21(11):1852-1857.
  • 9Sirpal S.Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease[J].Clin Sci (Lond),2009,116(9):681-695.
  • 10Gross ML,Piecha G, Bierhaus A,et al.Glycated and carbamylated albumin are more "nephrotoxic"than unmodified albumin in the amphibian kidney [J].Am J Physiol Renal Physiol,2011,301 (3): F476-F485.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部